H.C. Wainwright analyst Andrew Fein assumed coverage of MetaVia (MTVA) with a Buy rating and $12 price target The firm says Metavia offers a “compelling opportunity” in the metabolic disease space based on its two “differentiated” pipeline programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTVA:
- MetaVia Inc. Reports Q2 2025 Financial Results and Strategic Progress
- Optimistic Buy Rating for MetaVia Driven by Promising Obesity Drug Developments and Strategic Collaborations
- MetaVia Highlights Clinical Trials and Future Plans
- MetaVia Extends Phase 1 Trial for Obesity Drug
- MetaVia extends Phase 1 clinical trial of DA-1726